Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 955,063
  • Shares Outstanding, K 170,852
  • Annual Sales, $ 183,980 K
  • Annual Income, $ 46,290 K
  • 60-Month Beta 1.15
  • Price/Sales 5.19
  • Price/Cash Flow 43.97
  • Price/Book 5.43
Trade ATRS with:
  • Price/Earnings ttm 79.86
  • Earnings Per Share ttm 0.07
  • Most Recent Earnings -0.01 on 05/10/22
  • Next Earnings Date 05/19/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 115.30%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.01
  • Number of Estimates 4
  • High Estimate 0.02
  • Low Estimate 0.00
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.54 +0.90%
on 05/12/22
5.60 -0.18%
on 05/23/22
+0.02 (+0.36%)
since 04/22/22
3-Month
3.24 +72.53%
on 02/24/22
5.60 -0.18%
on 05/23/22
+2.22 (+65.88%)
since 02/23/22
52-Week
3.11 +79.74%
on 01/28/22
5.60 -0.18%
on 05/23/22
+1.51 (+37.01%)
since 05/21/21

Most Recent Stories

More News
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme...

ATRS : 5.59 (unch)
HALO : 44.48 (+1.09%)
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS

Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders...

ATRS : 5.59 (unch)
HALO : 44.48 (+1.09%)
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

NVAX : 57.15 (+11.12%)
ACET : 14.68 (+0.55%)
ATRS : 5.59 (unch)
ASRT : 3.15 (+6.78%)
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme...

ATRS : 5.59 (unch)
HALO : 44.48 (+1.09%)
Halozyme (HALO) to Acquire Antares for Auto Injector Platform

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

GSK : 43.75 (+0.51%)
PFE : 52.31 (-0.23%)
HALO : 44.48 (+1.09%)
ATRS : 5.59 (unch)
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

ONCY : 0.9900 (-1.98%)
ONC.TO : 1.26 (-3.82%)
GSK : 43.75 (+0.51%)
SRRA : 54.99 (+0.04%)
ATRS : 5.59 (unch)
CLVS : 2.85 (+58.33%)
TPTX : 75.11 (-0.19%)
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

ATRS : 5.59 (unch)
BDX : 251.80 (+2.14%)
Delta, Fastenal rise; JPMorgan Chase, NanoString fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:

ASH : 103.67 (+0.60%)
FAST : 49.74 (-0.36%)
ATRS : 5.59 (unch)
DAL : 29.52 (+1.90%)
JPM : 114.05 (+1.28%)
Why Is Sierra Oncology (SRRA) Stock Up Today?

Sierra Oncology is soaring following big acquisition news

SRRA : 54.99 (+0.04%)
ATRS : 5.59 (unch)
GILD : 62.36 (+0.89%)
HALO : 44.48 (+1.09%)
GSK : 43.75 (+0.51%)
Why Is BriaCell (BCTX) Stock Moving Today?

BCTX is experiencing heavy trading today

PYPL : 71.40 (+2.23%)
BCTX : 6.08 (+5.37%)
ATRS : 5.59 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

3rd Resistance Point 5.62
2nd Resistance Point 5.61
1st Resistance Point 5.60
Last Price 5.59
1st Support Level 5.58
2nd Support Level 5.57
3rd Support Level 5.56

See More

52-Week High 5.60
Last Price 5.59
Fibonacci 61.8% 4.65
Fibonacci 50% 4.36
Fibonacci 38.2% 4.06
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar